TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05985356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: iTBS targeting the left dorsolateral prefrontal cortex; 20 sessions over 4 weeks.
Study: NCT05062577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ASP8062
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: sublingual

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: buprenorphine/naloxone
Description: sublingual
Study: NCT05495334

Intervention type: PROCEDURE
Intervention: Treatment for Knee OA
Description: Pain management treatment for knee OA.
Study: NCT04234022

Intervention type: DRUG
Intervention: Lanalidomide with Zn-DDC
Description: Lanalidomide with Zn-DDC added to myeloma samples for culturing
Study: NCT05746247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testing centralized referral mechanism for PCPs
Description: For patients with a Penn PCP, we are testing a centralized referral mechanism to increase the number of referrals to preventive cardiology (default/opt out referrals)~For default/opt out: PCPs will receive a pended order for a referral for their patient to see a lipid specialist for a formal FH evaluation. Not interacting with the pended order or accepting the pended order will indicate that the referral to a lipid specialist should be placed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation
Description: All eligible patients will be informed that they have been identified by the FIND FH tool as potentially having familial hypercholesterolemia. All patients will be invited to schedule a telehealth appointment with a lipid specialist for a formal evaluation for FH.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation
Description: All eligible patients will be informed that they have been identified by the FIND FH tool as potentially having familial hypercholesterolemia. All patients will be invited to schedule a telehealth appointment with a lipid specialist for a formal evaluation for FH.
Study: NCT05430334

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: e-liquid 1
Description: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: e-liquid 2
Description: 30/70 PG/VG ratio with nicotine concentration 10mg/ml protonated

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: e-liquid 3
Description: 30/70 PG/VG ratio with nicotine concentration 4mg/ml free base
Study: NCT04234022

Intervention type: DRUG
Intervention: Pomalidomide with Zn-DDC
Description: Lanalidomide with Zn-DDC added to myeloma samples for culturing
Study: NCT05430334

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: e-liquid 4
Description: 30/70 PG/VG ratio with nicotine concentration 10mg/ml freebase

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: e-liquid 5
Description: 30/70 PG/VG ratio with nicotine concentration 0mg/ml (placebo)
Study: NCT06537544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Rehabilitation Program
Description: Pelvic Floor Muscle Strengthening Exercises Core Strengthening Exercises Breathing Exercises Patient education about bladder diary Postural education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pelvic Floor Training
Description: Kegels exercises in different body positions
Study: NCT05219617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\]).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carisbamate
Description: Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\]).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carisbamate
Description: Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\]).
Study: NCT04961814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liberal fasting
Description: preoperative fasting according to 6-4-0 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard fasting
Description: preoperative fasting according to 6-4-2 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
Study: NCT05192174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIB101
Description: NIB101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIB101
Description: NIB101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIB101
Description: NIB101
Study: NCT05609032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sense2Quit App
Description: Participants in the intervention arm will receive access to Sense2Quit, a smartphone app that links to a smartwatch.
Study: NCT04661150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 3 cycles prior to surgery and 5 cycles after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as an 8 mg/kg IV loading dose and then 6 mg/kg IV on Day 1 of a 21-day cycle for 3 cycles before surgery, and administration will continue after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered as an 8 mg/kg IV loading dose and then 6 mg/kg IV on Day 1 of a 21-day cycle for 3 cycles before surgery, and administration will continue after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m\^2 will be administered by IV on Day 1 of a 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m\^2 will be administered by IV on Day 1 of a 21-day cycle.
Study: NCT05632731

Intervention type: PROCEDURE
Group type: OTHER
Intervention: double cleavage-stage or single blastocyst stage embryos transfer
Description: Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: double cleavage-stage or single blastocyst stage embryos transfer
Description: Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.
Study: NCT06240689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is administered intravenously on the first day of each cycle. 21 days per cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.
Study: NCT05424614

Intervention type: OTHER
Intervention: Functional outcome follow-up of patients
Description: Patients were followed up by telephone after discharge, every 4 weeks, until the end of the 3-month follow-up. Their functional status was determined based on the MRS score (modified Rankin Scale). Those with less than 3 points were defined as having a good prognosis, and those with more than 3 points were defined as having a poor prognosis
Study: NCT06444113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatunumab
Description: No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
Study: NCT05016934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A vaccine composed of a recombinant S1 antigen
Description: Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A vaccine composed of a recombinant S1 antigen
Description: Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A vaccine composed of a recombinant S1 antigen
Description: Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: A vaccine composed of a recombinant S1 antigen
Description: Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein
Study: NCT04518137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle
Description: 48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle
Study: NCT05017558

Intervention type: DIAGNOSTIC_TEST
Intervention: point of care
Description: HIV-1 infected women will benefit from a viral load measurement by POC (Cepheid GenXpert HIV-1 viral load) at the time of delivery.~Newborns will benefit :~1. Antiretroviral preventive treatment differentiated according to their risk of infection in accordance with national recommendations:~   * High risk (maternal VL ≥1000 cp/ml): AZT/NVP for 12 weeks.~  * Low risk (maternal VL \<1000 cp/ml): NVP for 6 weeks.~2. virological screening for HIV by qualitative POC (Cepheid GenXpert HIV-1 qual) from birth (for high-risk newborns) at 6 weeks, at 9 months and at any time in the event of clinical manifestations suggestive of HIV infection.~3. In the event of a positive HIV test, the child will initiate immediately AZT/3TC/LPV/r~4. support from volunteers to improve retention in care, promotion of exclusive breastfeeding and family nutritional support
Study: NCT06341894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor dalpiciclib, 100mg orally qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Fulvestrant/AI
Study: NCT05124730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500mg prolonged release tablets (JSC Farmak, Ukraine)
Description: One tablet of the Test product was administered orally with 240 mL of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
Description: One tablet of Reference (R) Product was administered orally with 240 mL of water.
Study: NCT05136170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenegermin
Description: Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle was instilled with the same scheme of the test product
Study: NCT06544915

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Synbiotic, Probiotic, Placebo
Description: Use of dietary supplements to improve gut microbiome and cardiometabolic health

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic, Probiotic, Placebo
Description: Use of dietary supplements to improve gut microbiome and cardiometabolic health

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic, Probiotic, Placebo
Description: Use of dietary supplements to improve gut microbiome and cardiometabolic health
Study: NCT05225922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Partner Training
Description: This intervention aims to improve the language, communication, participation and overall quality of life of the Person with Aphasia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Speech and language Therapy
Description: This group will receive usual speech and language therapy session.
Study: NCT05966519

Intervention type: DEVICE
Intervention: Total Knee Replacement (TKR)
Description: Damaged cartilage of knee due to degenerative disease is replaced with metallic and plastic protheses
Study: NCT04418466

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone Implant

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone Implant
Study: NCT06174740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-cued audiovisual motor training
Description: In addition to visual cues, music stimuli guide finger sequence movement both rhythmically (temporal component) and sonically (pitch-finger alignment).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visually-cued motor training
Description: Visual cues guide finger sequence movement by indicating which finger to move in alignment with the position and of the visual cue.
Study: NCT06642675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation(iTBS)
Description: By using the TMS Navigation System, the iTBS will be targeted at the left Supramarginal Gyrus.iTBS will be performed using Magstim Rapid² stimulator, parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 1800 pulses per session, intensity of 90% resting motor threshold(RMT), total duration of 10 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Patients in sham group would receive the same intervention procedure as the active ITBS group, but the coil will be replaced with sham coil, which provides the sensation of TBS without enough magnetic energy to reach the cortex.
Study: NCT06413914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral Therapy
Description: Cognitive behavioral therapy is the psychological approach in this study. It is associated with better outcomes of rehabilitation for long-term pain in general, reduced pain intensity and less use of medication and health services, sustaining factors that provide an understanding of how thoughts and feelings affect the experience of pain. An important aim is also a reduction in pain-related rumination and worry and changed metacognition that maintains inhibiting behavior and thought patterns.~A workbook for pain has been developed. It contains knowledge about pain and pain management, describes measures and homework from session to session. The treatment consists of 8 sessions with 7 weekly sessions + 1 booster session 2 months after the end of treatment.~.
Study: NCT05505916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900 600 mg
Description: KVD900 Tablet 600 mg (2 x 300 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900 300 mg
Description: KVD900 Tablet 300 mg
Study: NCT06153082

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: In ROTEM group if CT EXTEM \>80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM \<35 and MCF FIBTEM \<8 CRYO or Fibrinogen concentrate, if MCF EXTEM\<35 and MCF FIBTEM \>8 Platelet, CL LY\>50 Trenaxemic acid
Study: NCT05387746

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caring Science, Mindful Practice and Reiki Training
Description: Participants will complete a) 4 week internet-based course on Caring Science Mindful Practice and b) 12 hour Reiki training. The participants will also complete online post-training survey with the same questions included in pre-training survey.
Study: NCT06153082

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Thromboelastography
Description: Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°.
Study: NCT04828486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05000710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab administered IV over 60 minutes at a dose of 1500 mg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab administered IV over 60 minutes at a dose of 300 mg , twice: at C1D1 and C4D1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose irradiation
Description: 21 days after the first immunotherapy treatment 11 fractions of 3 Gy will be administrated to metastatic or primary lesion/s over 2 weeks and one day
Study: NCT04530799

Intervention type: OTHER
Intervention: Identification of biomarkers for IAPA via patient sampling
Description: Blood, BAL, microbiome

Intervention type: OTHER
Intervention: Identification of biomarkers for IAPA via patient sampling
Description: Blood, BAL, microbiome
Study: NCT04240561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High level of signal manipulation
Description: Hearing aid will be programmed to a high level of signal manipulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High level of signal manipulation
Description: Hearing aid will be programmed to a high level of signal manipulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level of signal manipulation
Description: Hearing aid will be programmed to a low level of signal manipulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level of signal manipulation
Description: Hearing aid will be programmed to a low level of signal manipulation.
Study: NCT06564792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Once weekly contingency management visit involving 15 minutes+ of motivational interviewing and provision of incentives for stimulant-negative urine tests and/or tenofovir-positive urine tests.
Study: NCT04958057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAIL
Description: 6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
Study: NCT05210816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
Study: NCT05189665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraperitoneal high sacral ligament suspension surgery
Description: The extraperitoneal high sacral ligament suspension surgery is to shorten the bilateral uterosacral ligaments .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacrospinous ligament fixation
Description: The sacrospinous ligament fixation surgery is to open the front and back peritoneum through the vagina and shorten the bilateral uterosacral ligaments.
Study: NCT05664373

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap and deepithelized free gingival graft
Description: Free gingival grafts, de-epithelialized intraoraly or extraoraly in combination with coronally advanced flap will be used in the treatment of multiple gingival recessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap and deepithelized free gingival graft
Description: Free gingival grafts, de-epithelialized intraoraly or extraoraly in combination with coronally advanced flap will be used in the treatment of multiple gingival recessions.
Study: NCT06554769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non rigid indirect anchorage connection
Description: a nonrigid connection is placed between the miniscrews and the second premolar to prevent mesial tooth movement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rigid indirect anchorage connection
Description: a rigid connection is placed between the miniscrews and the first molar to prevent mesial tooth movement.